title: Combined intra-arterial infusion and systemic chemoradiotherapy for stage IV squamous cell carcinoma of the mandibular gingiva.
abstract: OBJECTIVE
  The purpose of this study was to show the effectiveness of combining intra-arterial infusion and systemic chemotherapy with concurrent radiotherapy for treatment of stage IV mandibular gingival cancer.
  
  
  METHODS
  A total of 23 patients with mandibular gingival cancer were treated with either docetaxel by intra-arterial infusion followed by systemic chemoradiotherapy with cisplatinum and 5-fluorouracil as a monthly regimen, or with docetaxel and cisplatinum by intra-arterial infusion followed by systemic chemoradiotherapy with 5-fluorouracil as a weekly or biweekly regimen. Tumor responses, locoregional control, overall survival, disease-specific survival, and adverse events were evaluated.
  
  
  RESULTS
  Of the 23 patients enrolled in the study, 22 completed the treatment. With regard to clinical stages, 82 % were diagnosed as IVA and 18 % IVB. Complete and partial response was observed in 82 and 18 %, respectively. Five-year overall survival, disease-specific survival, and locoregional control were 51, 70, and 72 %, respectively. No statistically significant difference was seen between the monthly regimen and the weekly plus biweekly regimen, although the latter resulted in longer survival and 88 % control.
  
  
  CONCLUSIONS
  Combined intra-arterial infusion and systemic chemoradiotherapy may be an effective treatment for patients with stage IV mandibular gingival cancer.
authors.affiliation: Department of Radiology, School of Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan. nakasato@iwate-med.ac.jp
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Nakasato
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Izumisawa
authors.forename: Akio
authors.initials: A
authors.lastname: Akahane
authors.forename: Koyo
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Ehara
authors.forename: Satoru
authors.initials: S
authors.lastname: Shoji
authors.forename: Shintaro
authors.initials: S
authors.lastname: Kogi
authors.forename: Harumi
authors.initials: H
authors.lastname: Mizuki
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sugiyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005887:Gingival Neoplasms / Q000628:therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008334:Mandible; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil